AI Article Synopsis
- The study aims to create a standard for diagnosing ocular metastasis (OM) in menopausal women with breast cancer and examines the role of specific biomarkers like CA-153 and CA-125.
- A sample of 1,362 menopausal breast cancer patients was analyzed, revealing a 1.6% incidence of OM and indicating that certain biomarkers are linked to this condition.
- Results showed that CA-153 and CA-125 had high sensitivity and specificity for diagnosing OM, suggesting that serum CA-153 is a strong predictor for OM in menopausal breast cancer patients, with implications for clinical practice.
Article Abstract
Aim: To establish a meaningful standard for diagnosing ocular metastasis (OM) in menopausal breast cancer (BC) women, and explore the relationship between CA-153, CA-125, apolipoprotein A, and OM.
Methods: A total of 1362 menopausal female BC patients with OM volunteered to take part in this study between July 2012 and July 2022. Women with BC who are menopausal were found to have an OM incidence of 1.6%. Furthermore, CA-153, CA-125, and apolipoprotein A (Apo A) all contributed to OM in women with BC who are postmenopausal according to binary logistic regression. Receiver operating curve (ROC) analysis was used to assess the diagnostic value of OM in patients with BC.
Results: Both CA-153 and CA-153+CA-125 showed a higher sensitivity of 95.45%, whereas CA-153+Apo A illustrated the highest specificity of 99.02%. Moreover, CA-153 and CA-153+CA-125 had higher areas under the curve (AUC) of 0.973.
Conclusion: The data indicate that the serum concentrations of CA-153 exhibited the most significant predictors of the diagnosis of OM in menopausal women with BC. The current study researches the utility of risk factors in predicting of OM in menopausal BC women and put forward the latest suggestions on their clinical application.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589442 | PMC |
| http://dx.doi.org/10.18240/ijo.2024.12.15 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive value of CA-153, CA-125 and Apo A for ocular metastasis in menopausal female patients with breast cancer.
Int J Ophthalmol
December 2024
Department of Ophthalmology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Article Synopsis
- The study aims to create a standard for diagnosing ocular metastasis (OM) in menopausal women with breast cancer and examines the role of specific biomarkers like CA-153 and CA-125.
- A sample of 1,362 menopausal breast cancer patients was analyzed, revealing a 1.6% incidence of OM and indicating that certain biomarkers are linked to this condition.
- Results showed that CA-153 and CA-125 had high sensitivity and specificity for diagnosing OM, suggesting that serum CA-153 is a strong predictor for OM in menopausal breast cancer patients, with implications for clinical practice.
Apo10 and TKTL1 in blood macrophages as potential biomarkers for early diagnosis of operable breast cancer.
Breast Cancer Res Treat
December 2024
Cancer Prevention Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfengdong Road, Yuexiu District, Guangzhou, 510060, Guangdong, China.
Objective: Blood macrophage Apo10 and TKTL1 detection is a novel, noninvasive cancer screening approach, but its relevance in breast cancer remains uncertain. We compared the potential diagnostic value of Apo10 and TKTL1 with commonly used tumor markers in differentiating breast cancer patients.
Methods: Physical examination and blood sample data from breast cancer patients who did not receive surgery or chemotherapy (retrospective; breast cancer group) and those with benign breast nodules and completely healthy subjects (prospective; control group) were collected from October 2020 to July 2022 at Sun Yat-sen University.
Biomarkers of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Front Immunol
November 2024
Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Background: Interstitial Lung Disease (ILD) represents the most common extra-articular manifestation of Rheumatoid Arthritis (RA) and is a major cause of mortality. This study aims to identify and evaluate biomarkers associated with Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).
Methods: We searched PubMed, Cochrane Library, EMBASE, and Web of Science databases for studies related to biomarkers of RA-ILD up until October 7, 2023.
Comparative accuracy of CA-153 and KL-6 as diagnostic and prognostic biomarkers for interstitial lung disease.
Clin Chim Acta
January 2025
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan; Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.
Backgrounds: To discern the potential of KL-6 and CA-153 as diagnostic tools for interstitial lung disease (ILD), understand their relationship with GAP (Gender, Age, and Physiology) stage, and analyze their predictive capacities alongside CT features. This research aims to enhance ILD detection and management in autoimmune patients, emphasizing the diagnostic utility of these biomarkers.
Methods: From Mar 2017 to Mar 2024, 398 patients from Taichung Veterans General Hospital's Division of Allergy, Immunology, and Rheumatology with autoimmune diseases were prospectively enrolled.
Association of serum tumor markers with serous effusion in systemic lupus erythematosus.
Heliyon
December 2023
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
The objective of this study was to investigate the relationship between serum tumor markers and serous effusion in systemic lupus erythematosus (SLE) patients, thereby contributing preliminary data on the utility of these tumor markers in diagnosing serous effusion. In this retrospective analysis, clinical data of SLE patients were extracted from electronic medical records. This included the levels of serum tumor markers, including pro-gastrin-releasing peptide, neuron-specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1), various carbohydrate antigens (CA 153, CA 125, CA 19-9), along with carcinoembryonic antigen, and alpha-fetoprotein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!